Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase, π in glioblastoma and the survival of the patients treated with nimustine hydrochloride:: An immunohistochemical analysis

被引:46
作者
Anda, T
Shabani, HK
Tsunoda, K
Tokunaga, Y
Kaminogo, M
Shibata, S
Hayashi, T
Iseki, M
机构
[1] Natl Nagasaki Med Ctr, Dept Neurosurg, Nagasaki 8568562, Japan
[2] Nagasaki Univ, Sch Med, Dept Neurosurg, Nagasaki 852, Japan
[3] Miyazaki Hosp, Dept Neurosurg, Miyazaki, Japan
[4] Nagasaki Univ Hosp, Dept Pathol, Nagasaki, Japan
[5] Nagasaki Univ, Inst Trop Med, Dept Pathol, Nagasaki 852, Japan
关键词
glioblastoma; drug resistance; MGMT; nimustine;
D O I
10.1179/016164103101201445
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Drug resistance is one of the important factors that determine-tumor response to chemotherapy. Several candidates for resistance to various chemotherapeutic agents have been elucidated. O-6-methylguanine-DNA methyltransferase (MGMT) removes methylation damage induced by nitrosourea from the O-6 position of DNA guanines before cell injury. Glutathione-S-transferase (GST) pi is also involved in nitrosourea resistance. We examined the expression of MGMT :and. GST. pi in 18 glioblastomas (GBM) using immunohistochemistry and compared the results with patients' survival after administration of 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethy;)-3-nitrosourea hydrochloride (ACNU)-based chemotherapy. According to the Kaplan-Meier's method, although median progression free survival (PFS) of eight patients whose tumors retained high MGMT (3+similar to2+), and 10 patients whose tumors showed low MGMT expression (1 + similar to0) were nine and 15 months, respectively (p = 0.09), median overall survival (OS) of the two groups were 12 and 22 months, respectively, which were significantly different (p = 0.01). GST pi expression in GBM was not a prognostic factor. It is suggested that GBM with strong staining of MGMT activity may show more resistance to ACNU-based chemotherapy compared to that with low MGMT. The simple immunohistochemical analysis of MGMT in GBM can be a useful method to determine whether ACNU or another treatment regimen should be recommended.
引用
收藏
页码:241 / 248
页数:8
相关论文
共 21 条
[11]   Application of antisense ribonucleic acid complementary to O-6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas [J].
Nagane, M ;
Asai, A ;
Shibui, S ;
Nomura, K ;
Kuchino, Y .
NEUROSURGERY, 1997, 41 (02) :434-440
[12]   O-6-METHYLGUANINE-DNA METHYLTRANSFERASE IN TUMORS AND CELLS OF THE OLIGODENDROCYTE LINEAGE [J].
NUTT, CL ;
COSTELLO, JF ;
BAMBRICK, LL ;
YAROSH, DB ;
SWINNEN, LJ ;
CHAMBERS, AF ;
CAIRNCROSS, JG .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1995, 22 (02) :111-115
[13]   EXPRESSION OF 06-METHYLGUANINE-DNA METHYLTRANSFERASE IN MALIGNANT HUMAN GLIOMA CELL-LINES [J].
OSTROWSKI, LE ;
VONWRONSKI, MA ;
BIGNER, SH ;
RASHEED, A ;
SCHOLD, SC ;
BRENT, TP ;
MITRA, S ;
BIGNER, DD .
CARCINOGENESIS, 1991, 12 (09) :1739-1744
[14]  
Rolhion C, 1999, INT J CANCER, V84, P416, DOI 10.1002/(SICI)1097-0215(19990820)84:4<416::AID-IJC15>3.0.CO
[15]  
2-A
[16]  
RUSSELL SJ, 1995, CANCER, V75, P1339, DOI 10.1002/1097-0142(19950315)75:6<1339::AID-CNCR2820750616>3.0.CO
[17]  
2-F
[18]  
Silber JR, 1998, CANCER RES, V58, P1068
[19]  
SILBER JR, 1993, CANCER RES, V53, P3416
[20]   Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes [J].
Tanaka, S ;
Kamitani, H ;
Amin, R ;
Watanabe, T ;
Oka, H ;
Fujii, K ;
Nagashima, T ;
Hori, T .
JOURNAL OF NEURO-ONCOLOGY, 2000, 46 (02) :157-171